These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 25331449)

  • 1. Do users of risperidone who switch brands because of generic reference pricing fare better or worse than non-switchers? A New Zealand natural experiment.
    Lessing C; Ashton T; Davis P
    Adm Policy Ment Health; 2015 Nov; 42(6):695-703. PubMed ID: 25331449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact on health outcome measures of switching to generic medicines consequent to reference pricing: the case of olanzapine in New Zealand.
    Lessing C; Ashton T; Davis PB
    J Prim Health Care; 2015 Jun; 7(2):94-101. PubMed ID: 26125054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact on health outcomes and healthcare utilisation of switching to generic medicines consequent to reference pricing: the case of lamotrigine in New Zealand.
    Lessing C; Ashton T; Davis P
    Appl Health Econ Health Policy; 2014 Oct; 12(5):537-46. PubMed ID: 25005492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Evaluation of Health Service Impacts Consequent to Switching from Brand to Generic Venlafaxine in New Zealand under Conditions of Price Neutrality.
    Lessing C; Ashton T; Davis P
    Value Health; 2015 Jul; 18(5):646-54. PubMed ID: 26297093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of generic switching on concerns about medicine and non-persistence among Danish adults in a general practice setting.
    Rathe JØ
    Dan Med J; 2015 Oct; 62(10):B5148. PubMed ID: 26441397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of patient co-payments on atypical antipsychotic choice in Poland: implications once generic atypicals are available.
    Wladysiuk M; Araszkiewicz A; Godman B; Szabert K; Barbui C; Haycox A
    Appl Health Econ Health Policy; 2011 Mar; 9(2):101-10. PubMed ID: 21271749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved?
    Cameron A; Mantel-Teeuwisse AK; Leufkens HG; Laing RO
    Value Health; 2012; 15(5):664-73. PubMed ID: 22867775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Zealand patients' understanding of brand substitution and opinions on copayment options for choice of medicine brand.
    Lessing C; Ashton T; Davis P
    Aust Health Rev; 2016 Jun; 40(3):345-350. PubMed ID: 26363980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications.
    Godman B; Petzold M; Bennett K; Bennie M; Bucsics A; Finlayson AE; Martin A; Persson M; Piessnegger J; Raschi E; Simoens S; Zara C; Barbui C
    BMC Med; 2014 Jun; 12():98. PubMed ID: 24927744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generic atypical antipsychotic drugs in Belgium: their influence and implications.
    Godman B; De Bruyn K; Miranda J; Raschi E; Bennie M; Barbui C; Simoens S
    J Comp Eff Res; 2013 Nov; 2(6):551-61. PubMed ID: 24236794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the effectiveness of brand-name and generic antipsychotic drugs for treating patients with schizophrenia in Taiwan.
    Hsu CW; Lee SY; Wang LJ
    Schizophr Res; 2018 Mar; 193():107-113. PubMed ID: 28629889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss.
    Treur M; Heeg B; Möller HJ; Schmeding A; van Hout B
    BMC Health Serv Res; 2009 Feb; 9():32. PubMed ID: 19226465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New antipsychotic drugs produce better outcomes.
    Healthc Benchmarks; 1997 Oct; 4(10):142-4. PubMed ID: 10173374
    [No Abstract]   [Full Text] [Related]  

  • 14. Resource use and cost implications of switching among warfarin formulations in atrial fibrillation patients.
    Kwong WJ; Kamat S; Fang C
    Ann Pharmacother; 2012 Dec; 46(12):1609-16. PubMed ID: 23150608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are specific initiatives required to enhance prescribing of generic atypical antipsychotics in Scotland?: International implications.
    Bennie M; Bishop I; Godman B; Barbui C; Raschi E; Campbell S; Miranda J; Gustafsson LL
    Int J Clin Pract; 2013 Feb; 67(2):170-80. PubMed ID: 23305478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time Series Analysis on the Impact of Generic Substitution and Reference Pricing on Antipsychotic Costs in Finland.
    Koskinen H; Mikkola H; Saastamoinen LK; Ahola E; Martikainen JE
    Value Health; 2015 Dec; 18(8):1105-12. PubMed ID: 26686797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of healthcare services by patients treated with risperidone versus conventional antipsychotic agents.
    Gianfrancesco F; Durkin MB; Mahmoud R; Wang RH
    Pharmacoeconomics; 2002; 20(6):413-27. PubMed ID: 12052100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eugenics by the back door? The unintended consequences of restricting people's choices about mental health medicines.
    Jones M; Lancashire S; Gurney S; Gray R
    J Psychiatr Ment Health Nurs; 2009 Oct; 16(8):758-61. PubMed ID: 19744065
    [No Abstract]   [Full Text] [Related]  

  • 19. The introduction of generic risperidone in Medicare Part D.
    Fung V; Price M; Busch AB; Landrum MB; Fireman B; Nierenberg AA; Newhouse JP; Hsu J
    Am J Manag Care; 2016 Jan; 22(1):41-8. PubMed ID: 26799124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis.
    Taylor DM; Wright T; Libretto SE;
    J Clin Psychiatry; 2003 May; 64(5):589-97. PubMed ID: 12755664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.